BTIG Reiterates Buy on Axcella Health Shares, Sees 211% Upside For The Stock

By George MacDonald

In a research report published on Sunday, BTIG analyst Julian Harrison reiterated a Buy rating on Axcella Health (NASDAQ:AXLA)with a price target of $16, which implies an upside of 211% from current levels.

With a return potential of 443.7%, the stock’s consensus target price stands at $28.00.